ArticleScientific reports2025
Recombinant ROP6 protein expressed in Saccharomyces cerevisiae INVSc1 cells induced strong immune response and provided significant protection against toxoplasmosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advances and Translational Challenges inVeterinary sciences · 2026Review
- Review
- Evaluation of immune protection of a multi-antigenic DNA vaccine encoding TgROP6 and TgMIC12 againstFrontiers in veterinary science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Toxoplasma gondii is a zoonotic parasite that infects almost all warm-blooded animals and humans and results in serious health problems. There is no drug treatment for chronic toxoplasmosis. Thus, a safe and protective vaccine is required by the community to combat against the chronic infection caused by T. gondii in humans and animals. Rhoptry (ROP) proteins of T. gondii have important roles in host cell invasion, penetration, and biogenesis of the parasitophorous vacuole. In this study, we aimed to develop a novel vaccine with recombinant ROP6 protein (rROP6), which was shown to be highly immunogenic in protein microarray screening with blood samples collected from animal models infected with T. gondii oocysts or tissue cysts. Initially, a comprehensive in silico analyses was performed to design ROP6 protein to be used as vaccine antigen. Then, rROP6 protein was expressed in Saccharomyces cerevisiae INVSc1 cells and purified by affinity chromatography. Next, rROP6 protein adjuvanted with Freund's (rROP6 + Freund) was administered to BALB/c mice two times at three-week intervals. Humoral and cellular immune responses were analyzed by Western blot, ELISA, flow cytometry, and cytokine ELISA. Protective efficacy was determined by orally infecting mice with T. gondii PRU strain tissue cysts. The level of protection was analyzed by investigating tissue cysts in brain homogenate of mice using microscopy and qPCR. According to the results, rROP6 + Freund induced a strong IgG response compared to only rROP6 (P < 0.01) and the rate of CD8
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.